Bayer
Bayer, Bicycle Therapeutics Partner to Develop Radiopharmaceuticals
Bayer will handle clinical development, manufacturing, and commercialization of radiopharmaceuticals discovered using Bicycle's platform.
Bayer, Telix Pharmaceuticals Partner to Study Nubeqa in Hormone-Sensitive Prostate Cancer
Telix will supply its PSMA imaging agent Illuccix, which Bayer will use to determine if patients have at least one PSMA-positive prostate cancer lesion at baseline.
Function Oncology Launches With $28M, Seeks to Transform Precision Cancer Therapy With CRISPR
Premium
The firm unveiled early validation data for its CRISPR-based functional genomics platform, which it hopes to commercialize as another tool doctors can use to individualize cancer care.
Bayer to Assess Nubeqa in High-Risk, Early-Stage Hormone-Sensitive Prostate Cancer
The firm will enroll patients to the Phase III clinical trial if they have a positive PSMA PET scan and their PSA score doubles within a year.
Ratio Therapeutics Raises $20M in Series A Financing
The firm, which launched last year with $20 million in seed funding, plans to use the money to develop targeted radiopharmaceuticals for patients with solid tumors.